Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells

Histone deacetylase inhibitors (HDACi) were identified nearly four decades ago based on their ability to induce cellular differentiation. However, the clinical development of these compounds as cancer therapies has focused on their capacity to induce apoptosis in hematologic and lymphoid malignancie...

Descripción completa

Detalles Bibliográficos
Autores principales: Cain, Jason E., McCaw, Andrew, Jayasekara, W. Samantha N., Rossello, Fernando J., Marini, Kieren D., Irving, Aaron T., Kansara, Maya, Thomas, David M., Ashley, David M., Watkins, D. Neil
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603321/
https://www.ncbi.nlm.nih.gov/pubmed/23533324
http://dx.doi.org/10.1155/2013/608964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3603321/
https://www.ncbi.nlm.nih.gov/pubmed/23533324
http://dx.doi.org/10.1155/2013/608964

Ejemplares similares